Abstract
IL-2 was first identified as a growth factor capable of driving the expansion of activated human T cell populations. In the more than 40 years since its discovery, a tremendous amount has been learned regarding the mechanisms that regulate the expression of both IL-2 and its cell surface receptor, its mechanisms of signalling and its range of biological actions. More recently, the mechanisms by which IL-2 regulates CD4+ T cell differentiation and function have been elucidated. IL-2 also regulates the effector and memory responses of CD8+ T cells, and the loss of IL-2 or responsiveness to IL-2 at least in part explains the exhausted phenotype that occurs during chronic viral infections and in tumour responses. These basic mechanistic studies have led to the therapeutic ability to manipulate the action of IL-2 on regulatory T (Treg) cells for the treatment of autoimmune disease and on CD8+ T cells for immunotherapy of cancer. IL-2 can have either positive or deleterious effects, and we discuss here recent ideas and approaches for manipulating the actions and overall net effects of IL-2 in disease settings, including cancer.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Morgan, D. A., Ruscetti, F. W. & Gallo, R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193, 1007–1008 (1976).
Robb, R. J., Munck, A. & Smith, K. A. T cell growth factor receptors. Quantitation, specificity, and biological relevance. J. Exp. Med. 154, 1455–1474 (1981).
Liao, W., Lin, J. X. & Leonard, W. J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38, 13–25 (2013).
Malek, T. R. & Castro, I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 33, 153–165 (2010).
Leonard, W. J. et al. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature 311, 626–631 (1984).
Nikaido, T. et al. Molecular cloning of cDNA encoding human interleukin-2 receptor. Nature 311, 631–635 (1984).
Hatakeyama, M. et al. Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA’s. Science 244, 551–556 (1989).
Takeshita, T. et al. Cloning of the gamma chain of the human IL-2 receptor. Science 257, 379–382 (1992).
Takeshita, T. et al. An associated molecule, p64, with IL-2 receptor beta chain. Its possible involvement in the formation of the functional intermediate-affinity IL-2 receptor complex. J. Immunol. 148, 2154–2158 (1992).
Wang, X., Lupardus, P., Laporte, S. L. & Garcia, K. C. Structural biology of shared cytokine receptors. Annu. Rev. Immunol. 27, 29–60 (2009).
Nakamura, Y. et al. Heterodimerization of the IL-2 receptor beta- and gamma-chain cytoplasmic domains is required for signalling. Nature 369, 330–333 (1994).
Nelson, B. H., Lord, J. D. & Greenberg, P. D. Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T cell proliferation. Nature 369, 333–336 (1994).
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151–1164 (1995).
Monticelli, L. A. et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat. Immunol. 12, 1045–1054 (2011).
Siegel, J. P., Sharon, M., Smith, P. L. & Leonard, W. J. The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science 238, 75–78 (1987).
Grimm, E. A., Mazumder, A., Zhang, H. Z. & Rosenberg, S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155, 1823–1841 (1982).
Schmitt, E. et al. IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-beta and IL-4, and is inhibited by IFN-gamma. J. Immunol. 153, 3989–3996 (1994).
Liao, W. et al. Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression. Proc. Natl Acad. Sci. USA 111, 3508–3513 (2014).
Malek, T. R., Yu, A., Vincek, V., Scibelli, P. & Kong, L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17, 167–178 (2002).
Liao, W., Lin, J. X., Wang, L., Li, P. & Leonard, W. J. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat. Immunol. 12, 551–559 (2011). This study demonstrates that IL-2 broadly influences T H cell differentiation.
Cote-Sierra, J. et al. Interleukin 2 plays a central role in Th2 differentiation. Proc. Natl Acad. Sci. USA 101, 3880–3885 (2004).
Liao, W. et al. Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor alpha-chain expression. Nat. Immunol. 9, 1288–1296 (2008).
Laurence, A. et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26, 371–381 (2007).
Ballesteros-Tato, A. et al. Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity 36, 847–856 (2012).
Lenardo, M. et al. Mature T lymphocyte apoptosis—immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol. 17, 221–253 (1999).
Weinberg, K. & Parkman, R. Severe combined immunodeficiency due to a specific defect in the production of interleukin-2. N. Engl. J. Med. 322, 1718–1723 (1990).
Pahwa, R. et al. Recombinant interleukin 2 therapy in severe combined immunodeficiency disease. Proc. Natl Acad. Sci. USA 86, 5069–5073 (1989).
Noguchi, M. et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73, 147–157 (1993).
Kondo, M. et al. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science 262, 1874–1877 (1993).
Russell, S. M. et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. Science 262, 1880–1883 (1993).
Noguchi, M. et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science 262, 1877–1880 (1993).
Russell, S. M. et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science 266, 1042–1045 (1994).
Kimura, Y. et al. Sharing of the IL-2 receptor gamma chain with the functional IL-9 receptor complex. Int. Immunol. 7, 115–120 (1995).
Giri, J. G. et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 13, 2822–2830 (1994).
Asao, H. et al. Cutting edge: the common gamma-hain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. 167, 1–5 (2001).
Kovanen, P. E. & Leonard, W. J. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol. Rev. 202, 67–83 (2004).
Recher, M. et al. IL-21 is the primary common gamma chain-binding cytokine required for human B cell differentiation in vivo. Blood 118, 6824–6835 (2011).
Ozaki, K. et al. A critical role for IL-21 in regulating immunoglobulin production. Science 298, 1630–1634 (2002).
Sharfe, N., Dadi, H. K., Shahar, M. & Roifman, C. M. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc. Natl Acad. Sci. USA 94, 3168–3171 (1997).
Willerford, D. M. et al. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3, 521–530 (1995).
Gilmour, K. C. et al. Defective expression of the interleukin-2/interleukin-15 receptor beta subunit leads to a natural killer cell-deficient form of severe combined immunodeficiency. Blood 98, 877–879 (2001).
Suzuki, H. et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 268, 1472–1476 (1995).
Rosenberg, S. A. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 192, 5451–5458 (2014).
Muller, M. R. & Rao, A. NFAT, immunity and cancer: a transcription factor comes of age. Nat. Rev. Immunol. 10, 645–656 (2010).
Rooney, J. W., Sun, Y. L., Glimcher, L. H. & Hoey, T. Novel NFAT sites that mediate activation of the interleukin-2 promoter in response to T cell receptor stimulation. Mol. Cell. Biol. 15, 6299–6310 (1995).
Flanagan, W. M., Corthesy, B., Bram, R. J. & Crabtree, G. R. Nuclear association of a T cell transcription factor blocked by FK-506 and cyclosporin A. Nature 352, 803–807 (1991).
Emmel, E. A. et al. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science 246, 1617–1620 (1989).
Kim, H. P., Imbert, J. & Leonard, W. J. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev. 17, 349–366 (2006).
Wu, Y. et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126, 375–387 (2006).
Shapiro, V. S., Truitt, K. E., Imboden, J. B. & Weiss, A. CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites. Mol. Cell. Biol. 17, 4051–4058 (1997).
Himes, S. R., Coles, L. S., Reeves, R. & Shannon, M. F. High mobility group protein I(Y) is required for function and for c-Rel binding to CD28 response elements within the GM-CSF and IL-2 promoters. Immunity 5, 479–489 (1996).
Tomkowicz, B. et al. TIM-3 suppresses anti-CD3/CD28-induced TCR activation and IL-2 expression through the NFAT signaling pathway. PLOS One 10, e0140694 (2015).
Yost, E. A., Hynes, T. R., Hartle, C. M., Ott, B. J. & Berlot, C. H. Inhibition of G-protein betagamma signaling enhances T cell receptor-stimulated interleukin 2 transcription in CD4 + T helper cells. PLOS One 10, e0116575 (2015).
Depper, J. M. et al. Regulation of interleukin 2 receptor expression: effects of phorbol diester, phospholipase C, and reexposure to lectin or antigen. J. Immunol. 133, 3054–3061 (1984).
Leonard, W. J., Kronke, M., Peffer, N. J., Depper, J. M. & Greene, W. C. Interleukin 2 receptor gene expression in normal human T lymphocytes. Proc. Natl Acad. Sci. USA 82, 6281–6285 (1985).
John, S., Robbins, C. M. & Leonard, W. J. An IL-2 response element in the human IL-2 receptor alpha chain promoter is a composite element that binds Stat5, Elf-1, HMG-I(Y) and a GATA family protein. EMBO J. 15, 5627–5635 (1996).
Kim, H. P., Kelly, J. & Leonard, W. J. The basis for IL-2-induced IL-2 receptor alpha chain gene regulation: importance of two widely separated IL-2 response elements. Immunity 15, 159–172 (2001).
Lecine, P. et al. Elf-1 and Stat5 bind to a critical element in a new enhancer of the human interleukin-2 receptor alpha gene. Mol. Cell. Biol. 16, 6829–6840 (1996).
Lin, J. X. et al. Critical role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. Immunity 36, 586–599 (2012).This study demonstrates the importance of STAT tetramers in vivo and shows that STAT5 tetramers fine-tune IL-2 signalling.
Li, P. et al. STAT5-mediated chromatin interactions in superenhancers activate IL-2 highly inducible genes: functional dissection of the Il2ra gene locus. Proc. Natl Acad. Sci. USA 114, 12111–12119 (2017). This study identifies a STAT5-based super-enhancer as the key regulatory element mediating IL-2-induced gene regulation of Il2ra and dissects the functional elements of the super-enhancer.
Li, G. et al. Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. Cell 148, 84–98 (2012).
Tang, Z. et al. CTCF-mediated human 3D genome architecture reveals chromatin topology for transcription. Cell 163, 1611–1627 (2015).
Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).
Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).
Komor, A. C., Badran, A. H. & Liu, D. R. CRISPR-based technologies for the manipulation of eukaryotic genomes. Cell 169, 20–36 (2017).
Simeonov, D. R. et al. Discovery of stimulation-responsive immune enhancers with CRISPR activation. Nature 549, 111–115 (2017). This study identifies the functional importance of a non-coding autoimmunity risk variant in the IL2RA gene and shows that the kinetics of IL2RA gene expression can be important for disease development.
Burren, O. S. et al. Chromosome contacts in activated T cells identify autoimmune disease candidate genes. Genome Biol. 18, 165 (2017).
Lin, J. X. & Leonard, W. J. The common cytokine receptor gamma chain family of cytokines. Cold Spring Harb. Perspect. Biol. (2017).
Ring, A. M. et al. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat. Immunol. 13, 1187–1195 (2012).
Markiewicz, S. et al. Tissue-specific activity of the gammac chain gene promoter depends upon an Ets binding site and is regulated by GA-binding protein. J. Biol. Chem. 271, 14849–14855 (1996).
Miyazaki, T. et al. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 266, 1045–1047 (1994).
Boussiotis, V. A. et al. Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science 266, 1039–1042 (1994).
Macchi, P. et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377, 65–68 (1995).
Russell, S. M. et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270, 797–800 (1995).
Friedmann, M. C., Migone, T. S., Russell, S. M. & Leonard, W. J. Different interleukin 2 receptor beta-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferation. Proc. Natl Acad. Sci. USA 93, 2077–2082 (1996).
Goldsmith, M. A. et al. Growth signal transduction by the human interleukin-2 receptor requires cytoplasmic tyrosines of the beta chain and non-tyrosine residues of the gamma c chain. J. Biol. Chem. 270, 21729–21737 (1995).
Dwyer, C. J. et al. Altered homeostasis and development of regulatory T cell subsets represent an IL-2R-dependent risk for diabetes in NOD mice. Sci. Signal. 10, eaam9563 (2017).
Lin, J. X. et al. Critical functions for STAT5 tetramers in the maturation and survival of natural killer cells. Nat. Commun. 8, 1320 (2017).
Smith, G. A., Uchida, K., Weiss, A. & Taunton, J. Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling. Nat. Chem. Biol. 12, 373–379 (2016).
Smith, G. A., Taunton, J. & Weiss, A. IL-2Rbeta abundance differentially tunes IL-2 signaling dynamics in CD4+ and CD8+ T cells. Sci. Signal. 10, eaan4931 (2017).
Ross, S. H. et al. Phosphoproteomic analyses of interleukin 2 signaling reveal integrated JAK kinase-dependent and -independent networks in CD8+ T cells. Immunity 45, 685–700 (2016).
Szabo, S. J., Sullivan, B. M., Peng, S. L. & Glimcher, L. H. Molecular mechanisms regulating Th1 immune responses. Annu. Rev. Immunol. 21, 713–758 (2003).
Oestreich, K. J., Mohn, S. E. & Weinmann, A. S. Molecular mechanisms that control the expression and activity of Bcl-6 in TH1 cells to regulate flexibility with a TFH-like gene profile. Nat. Immunol. 13, 405–411 (2012).
Oestreich, K. J. et al. Bcl-6 directly represses the gene program of the glycolysis pathway. Nat. Immunol. 15, 957–964 (2014).
Ray, J. P. et al. The interleukin-2-mTORc1 kinase axis defines the signaling, differentiation, and metabolism of T helper 1 and follicular B helper T cells. Immunity 43, 690–702 (2015).
Zhu, J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine 75, 14–24 (2015).
Zhu, J., Cote-Sierra, J., Guo, L. & Paul, W. E. Stat5 activation plays a critical role in Th2 differentiation. Immunity 19, 739–748 (2003). This is the initial report demonstrating that STAT5 activation during T H 2 cell polarization is a crucial event for the production of IL-4.
Hondowicz, B. D. et al. Interleukin-2-dependent allergen-specific tissue-resident memory cells drive asthma. Immunity 44, 155–166 (2016).
Burkett, P. R., Meyer zu Horste, G. & Kuchroo, V. K. Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity. J. Clin. Invest. 125, 2211–2219 (2015).
Ciofani, M. et al. A validated regulatory network for Th17 cell specification. Cell 151, 289–303 (2012).
Yang, X. P. et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat. Immunol. 12, 247–254 (2011).
Quintana, F. J. et al. Aiolos promotes TH17 differentiation by directly silencing Il2 expression. Nat. Immunol. 13, 770–777 (2012).
Kim, H. S. et al. PTEN drives Th17 cell differentiation by preventing IL-2 production. J. Exp. Med. 214, 3381–3398 (2017).
Amadi-Obi, A. et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat. Med. 13, 711–718 (2007).
Kaplan, M. H. Th9 cells: differentiation and disease. Immunol. Rev. 252, 104–115 (2013).
Moretti, S. et al. A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis. Nat. Commun. 8, 14017 (2017).
Josefowicz, S. Z., Lu, L. F. & Rudensky, A. Y. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531–564 (2012).
Chinen, T. et al. An essential role for the IL-2 receptor in Treg cell function. Nat. Immunol. 17, 1322–1333 (2016).
Josefowicz, S. Z. & Rudensky, A. Control of regulatory T cell lineage commitment and maintenance. Immunity 30, 616–625 (2009).
Chung, Y. et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat. Med. 17, 983–988 (2011).
Busse, D. et al. Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments. Proc. Natl Acad. Sci. USA 107, 3058–3063 (2010).
Liu, Z. et al. Immune homeostasis enforced by co-localized effector and regulatory T cells. Nature 528, 225–230 (2015).In this study, the authors use a new method, histocytometry, for phenotyping cells within a tissue with regard to their functional state and their activation state.
Amado, I. F. et al. IL-2 coordinates IL-2-producing and regulatory T cell interplay. J. Exp. Med. 210, 2707–2720 (2013).
Sitrin, J., Ring, A., Garcia, K. C., Benoist, C. & Mathis, D. Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2. J. Exp. Med. 210, 1153–1165 (2013).
Gasteiger, G. et al. IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells. J. Exp. Med. 210, 1167–1178 (2013).
Johnston, R. J. et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 325, 1006–1010 (2009).
Leon, B., Bradley, J. E., Lund, F. E., Randall, T. D. & Ballesteros-Tato, A. FoxP3 + regulatory T cells promote influenza-specific Tfh responses by controlling IL-2 availability. Nat. Commun. 5, 3495 (2014).
Linterman, M. A. et al. Foxp3 + follicular regulatory T cells control the germinal center response. Nat. Med. 17, 975–982 (2011).
Botta, D. et al. Dynamic regulation of T follicular regulatory cell responses by interleukin 2 during influenza infection. Nat. Immunol. 18, 1249–1260 (2017).This study characterizes the temporal sequence of IL-2 production and its effect on the production of T FR cells and T reg cells after influenza virus infection.
Jandl, C. et al. IL-21 restricts T follicular regulatory T cell proliferation through Bcl-6 mediated inhibition of responsiveness to IL-2. Nat. Commun. 8, 14647 (2017).
Wing, J. B. et al. A distinct subpopulation of CD25(-) T-follicular regulatory cells localizes in the germinal centers. Proc. Natl Acad. Sci. USA 114, E6400–E6409 (2017).
Henning, A. N., Roychoudhuri, R. & Restifo, N. P. Epigenetic control of CD8+ T cell differentiation.Nat. Rev. Immunol. 18, 340–356 (2018).
Kalia, V. et al. Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. Immunity 32, 91–103 (2010).
Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486–499 (2015).
Gong, D. & Malek, T. R. Cytokine-dependent Blimp-1 expression in activated T cells inhibits IL-2 production. J. Immunol. 178, 242–252 (2007).
Boulet, S., Daudelin, J. F. & Labrecque, N. IL-2 induction of Blimp-1 is a key in vivo signal for CD8 + short-lived effector T cell differentiation. J. Immunol. 193, 1847–1854 (2014).
Xin, A. et al. A molecular threshold for effector CD8+ T cell differentiation controlled by transcription factors Blimp-1 and T-bet. Nat. Immunol. 17, 422–432 (2016).
Beltra, J. C. et al. IL2Rbeta-dependent signals drive terminal exhaustion and suppress memory development during chronic viral infection. Proc. Natl Acad. Sci. USA 113, E5444–5453 (2016).
Blattman, J. N. et al. Therapeutic use of IL-2 to enhance antiviral T cell responses in vivo. Nat. Med. 9, 540–547 (2003).
West, E. E. et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J. Clin. Invest. 123, 2604–2615 (2013).This paper demonstrates that combinatorial therapy with both IL-2 and PDL1 blockade could be effective in the activation of exhausted T cells.
Moynihan, K. D. et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat. Med. 22, 1402–1410 (2016).
Cully, M. Deal watch: IL-2 focus switches to stimulating Tregs. Nat. Rev. Drug Discov. 16, 595 (2017).
Letourneau, S. et al. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc. Natl Acad. Sci. USA 107, 2171–2176 (2010).
Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D. & Sprent, J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311, 1924–1927 (2006).This is an early demonstration of cell-subset-specific effects of antibodies against IL-2.
Krieg, C., Letourneau, S., Pantaleo, G. & Boyman, O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc. Natl Acad. Sci. USA 107, 11906–11911 (2010).
Arenas-Ramirez, N. et al. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2. Sci. Transl Med. 8, 367ra166 (2016).
Spangler, J. B. et al. Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms. Immunity 42, 815–825 (2015).This study provides a mechanistic understanding of differences in cell type specificity of IL-2-targeting antibodies, leading to the ability to specifically engineer therapeutic antibodies.
Webster, K. E. et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J. Exp. Med. 206, 751–760 (2009).
Tang, Q. et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687–697 (2008).
Arce Vargas, F. et al. Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity 46, 577–586 (2017).
Vazquez-Lombardi, R. et al. Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T cells. Nat. Commun. 8, 15373 (2017).
Koreth, J. et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365, 2055–2066 (2011).
Grinberg-Bleyer, Y. et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J. Exp. Med. 207, 1871–1878 (2010).
Saadoun, D. et al. Regulatory T cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 365, 2067–2077 (2011).
He, J. et al. Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus. Nat. Med. 22, 991–993 (2016).
Humrich, J. Y. et al. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann. Rheum. Dis. 74, 791–792 (2015).
Mitra, S. et al. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity 42, 826–838 (2015).This study describes IL-2 variants that represent the first cytokine partial agonists, including one with differential effects depending on the activation state of the cell and another that is a potent IL-2 antagonist and is effective as an IL-2 blocking agent both in vivo and in vitro.
Levin, A. M. et al. Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’. Nature 484, 529–533 (2012).
Kagoya, Y. et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat. Med. 24, 352–359 (2018).This study describes an engineered CAR in which antigen can signal through the CAR and activate JAK–STAT3–STAT5 signalling pathways, leading to more effective antitumour activity in vivo.
Sockolosky, J. T. et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science 359, 1037–1042 (2018).This paper describes a method for engineering tumour-specific T cells that can be selectively expanded in vivo via the interaction of a mutant form of IL-2 with an altered IL-2 receptor.
Schwartz, D. M. et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 16, 843–862 (2017).
Telliez, J. B. et al. Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition. ACS Chem. Biol. 11, 3442–3451 (2016).
Thorarensen, A. et al. Design of a janus kinase 3 (JAK3) specific inhibitor 1-((2 S,5 R)-5-((7 H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop -2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans. J. Med. Chem. 60, 1971–1993 (2017).
Acknowledgements
This work was supported by the Division of Intramural Research, National Heart, Lung, and Blood Institute, US National Institutes of Health.
Reviewer information
Nature Reviews Immunology thanks O. Boyman and T. Malek for their contribution to the peer review of this work.
Author information
Authors and Affiliations
Contributions
All authors contributed to research and discussion of content of the article and to writing, reviewing and editing of the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
W.J.L. is an inventor on patents related to IL-2 partial agonists. R.S. and P.L. declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Related links
ClinicalTrials.gov: https://www.clinicaltrials.gov
Glossary
- X-linked severe combined immunodeficiency
-
(XSCID). A profound immunodeficiency that accounts for approximately half of all cases of SCID. It is characterized by greatly diminished numbers of T cells and natural killer cells. B cells are normal in number but are non-functional.
- Super-enhancer
-
A cluster of transcriptional regulatory elements, often spanning an extended region, that functionally modulate gene expression as a unit.
- Chromatin interaction analysis using paired-end tag sequencing
-
(ChIA-PET). A method for identifying pairs of regions associated with a particular protein by combining chromatin immunoprecipitation with the isolation of interacting DNA fragments.
- Tiled CRISPR activation
-
The use of CRISPR activation (CRISPRa) for high-throughput functional enhancer discovery with libraries of guide RNAs that tile genomic loci of interest.
- Promoter capture Hi-C
-
The incorporation of a sequence capture step into a Hi-C protocol to enable high-resolution analysis of annotated promoters and their interacting regions from Hi-C libraries.
- Chronic-smouldering forms of adult T cell leukaemia/lymphoma
-
As opposed to the more aggressive acute and lymphomatous forms of adult T cell leukaemia, the chronic and smouldering forms are slow-growing forms of the disease, with milder symptoms. These leukaemias are caused by human T cell lymphotropic virus type 1.
Rights and permissions
About this article
Cite this article
Spolski, R., Li, P. & Leonard, W.J. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat Rev Immunol 18, 648–659 (2018). https://doi.org/10.1038/s41577-018-0046-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41577-018-0046-y
This article is cited by
-
The clinical significance of plasma sCD25 as valuable biomarker for progression and prognosis of tuberculosis
BMC Infectious Diseases (2024)
-
i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists
Nature Communications (2024)
-
Differential Regulation of Immune-Related Genes in the Developing Heart
Pediatric Cardiology (2024)
-
NK cells as powerful therapeutic tool in cancer immunotherapy
Cellular Oncology (2024)
-
Epigenetic Insights Into Necrotizing Enterocolitis: Unraveling Methylation-Regulated Biomarkers
Inflammation (2024)